A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
To determine the appropriate time of concomitant chemotherapy administration after antiangiogenic treatment, we investigated the timing and effect of bevacizumab administration on vascular normalization of metastatic brain tumors in breast cancer patients. Eight patients who participated in a phase...
Gespeichert in:
| Veröffentlicht in: | BMC cancer 2016-07, Vol.16 (1), p.466-466, Article 466 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 466 |
|---|---|
| container_issue | 1 |
| container_start_page | 466 |
| container_title | BMC cancer |
| container_volume | 16 |
| creator | Chen, Bang-Bin Lu, Yen-Shen Lin, Ching-Hung Chen, Wei-Wu Wu, Pei-Fang Hsu, Chao-Yu Yu, Chih-Wei Wei, Shwu-Yuan Cheng, Ann-Lii Shih, Tiffany Ting-Fang |
| description | To determine the appropriate time of concomitant chemotherapy administration after antiangiogenic treatment, we investigated the timing and effect of bevacizumab administration on vascular normalization of metastatic brain tumors in breast cancer patients.
Eight patients who participated in a phase II trial for breast cancer-induced refractory brain metastases were enrolled and subjected to 4 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examinations that evaluated Peak, Slope, iAUC 60 , and Ktrans before and after treatment. The treatment comprised bevacizumab on Day 1, etoposide on Days 2-4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles. DCE-MRI was performed before treatment and at 1 h, 24 h, and 21 days after bevacizumab administration.
Values of the 4 DCE-MRI parameters reduced after bevacizumab administration. Compared with baseline values, the mean reductions at 1 and 24 h were -12.8 and -24.7 % for Peak, -46.6 and -65.8 % for Slope, -27.9 and -55.5 % for iAUC 60 , and -46.6 and -63.9 % for Ktrans, respectively (all P |
| doi_str_mv | 10.1186/s12885-016-2494-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4944505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468887163</galeid><sourcerecordid>A468887163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c559t-34020548368c3dc7672ca7930112073db215dc35228e2cf3f5b9196c3ff569de3</originalsourceid><addsrcrecordid>eNptkltrFDEUxwdRbK1-AF8kIIg-TM1lMsm8CEvxUigIXp5DJnOymzKTrElmsX33e5tha90VCSHn8jsn5ORfVc8JPidEtm8ToVLyGpO2pk3X1PJBdUoaQYqHxcMD-6R6ktI1xkRILB9XJ1Q0hPKWnla_VmjrxpBRyvNwg3JAA2SIk_OA8qZsV8w10n5AYC2YjIJFPey0cbfzpHsUPNrpZOZRR-RDnPTobnV2JVzACbJOubgG9VE7j_I8hZhQsfoIJYWM9gbi0-qR1WOCZ3fnWfX9w_tvF5_qq88fLy9WV7XhvMs1azDFvJGslYYNRrSCGi06hgmhWLChp4QPhnFKJVBjmeV9R7rWMGt52w3Azqp3-77buZ9gMOBz1KPaRjfpeKOCduo4491GrcNOlek2HPPS4PVdgxh-zJCymlwyMI7aQ5iTIhI3koumwQV9-Q96Heboy_MWSnS0xYT9pdZ6BOW8DeVeszRVq6aVUgrSLtT5f6iyBpicCR6sK_GjgjdHBYXJ8DOv9ZySuvz65Zh9dcBuQI95k8I4L5-YjkGyB00MKUWw94MjWC2CVHtBqiJItQhSyVLz4nDi9xV_FMh-A-uA2lk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1807926013</pqid></control><display><type>article</type><title>A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chen, Bang-Bin ; Lu, Yen-Shen ; Lin, Ching-Hung ; Chen, Wei-Wu ; Wu, Pei-Fang ; Hsu, Chao-Yu ; Yu, Chih-Wei ; Wei, Shwu-Yuan ; Cheng, Ann-Lii ; Shih, Tiffany Ting-Fang</creator><creatorcontrib>Chen, Bang-Bin ; Lu, Yen-Shen ; Lin, Ching-Hung ; Chen, Wei-Wu ; Wu, Pei-Fang ; Hsu, Chao-Yu ; Yu, Chih-Wei ; Wei, Shwu-Yuan ; Cheng, Ann-Lii ; Shih, Tiffany Ting-Fang</creatorcontrib><description>To determine the appropriate time of concomitant chemotherapy administration after antiangiogenic treatment, we investigated the timing and effect of bevacizumab administration on vascular normalization of metastatic brain tumors in breast cancer patients.
Eight patients who participated in a phase II trial for breast cancer-induced refractory brain metastases were enrolled and subjected to 4 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examinations that evaluated Peak, Slope, iAUC 60 , and Ktrans before and after treatment. The treatment comprised bevacizumab on Day 1, etoposide on Days 2-4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles. DCE-MRI was performed before treatment and at 1 h, 24 h, and 21 days after bevacizumab administration.
Values of the 4 DCE-MRI parameters reduced after bevacizumab administration. Compared with baseline values, the mean reductions at 1 and 24 h were -12.8 and -24.7 % for Peak, -46.6 and -65.8 % for Slope, -27.9 and -55.5 % for iAUC 60 , and -46.6 and -63.9 % for Ktrans, respectively (all P < .05). The differences in the 1 and 24 h mean reductions were significant (all P < .05) for all the parameters. The generalized estimating equation linear regression analyses of the 4 DCE-MRI parameters revealed that vascular normalization peaked 24 h after bevacizumab administration.
Bevacizumab induced vascular normalization of brain metastases in humans at 1 and 24 h after administration, and the effect was significantly higher at 24 h than at 1 h.
ClinicalTrials.gov, identifier NCT01281696 , registered prospectively on December 24, 2010.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-016-2494-8</identifier><identifier>PMID: 27412562</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Analysis ; Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab - administration & dosage ; Bevacizumab - therapeutic use ; Brain cancer ; Brain Neoplasms - blood supply ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - drug therapy ; Brain Neoplasms - secondary ; Brain tumors ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cancer therapies ; Care and treatment ; Chemotherapy ; Cisplatin - administration & dosage ; Cisplatin - therapeutic use ; Clinical outcomes ; Contrast agents ; Contrast Media - administration & dosage ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Etoposide - administration & dosage ; Etoposide - therapeutic use ; Female ; Humans ; Hypotheses ; Magnetic resonance imaging ; Magnetic Resonance Imaging - methods ; Metastasis ; Middle Aged ; Neovascularization ; Patients ; Pilot Projects ; Prospective Studies ; Response rates ; Statistical analysis ; Time Factors ; Treatment Outcome ; Tumors</subject><ispartof>BMC cancer, 2016-07, Vol.16 (1), p.466-466, Article 466</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c559t-34020548368c3dc7672ca7930112073db215dc35228e2cf3f5b9196c3ff569de3</citedby><cites>FETCH-LOGICAL-c559t-34020548368c3dc7672ca7930112073db215dc35228e2cf3f5b9196c3ff569de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944505/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944505/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27412562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Bang-Bin</creatorcontrib><creatorcontrib>Lu, Yen-Shen</creatorcontrib><creatorcontrib>Lin, Ching-Hung</creatorcontrib><creatorcontrib>Chen, Wei-Wu</creatorcontrib><creatorcontrib>Wu, Pei-Fang</creatorcontrib><creatorcontrib>Hsu, Chao-Yu</creatorcontrib><creatorcontrib>Yu, Chih-Wei</creatorcontrib><creatorcontrib>Wei, Shwu-Yuan</creatorcontrib><creatorcontrib>Cheng, Ann-Lii</creatorcontrib><creatorcontrib>Shih, Tiffany Ting-Fang</creatorcontrib><title>A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>To determine the appropriate time of concomitant chemotherapy administration after antiangiogenic treatment, we investigated the timing and effect of bevacizumab administration on vascular normalization of metastatic brain tumors in breast cancer patients.
Eight patients who participated in a phase II trial for breast cancer-induced refractory brain metastases were enrolled and subjected to 4 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examinations that evaluated Peak, Slope, iAUC 60 , and Ktrans before and after treatment. The treatment comprised bevacizumab on Day 1, etoposide on Days 2-4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles. DCE-MRI was performed before treatment and at 1 h, 24 h, and 21 days after bevacizumab administration.
Values of the 4 DCE-MRI parameters reduced after bevacizumab administration. Compared with baseline values, the mean reductions at 1 and 24 h were -12.8 and -24.7 % for Peak, -46.6 and -65.8 % for Slope, -27.9 and -55.5 % for iAUC 60 , and -46.6 and -63.9 % for Ktrans, respectively (all P < .05). The differences in the 1 and 24 h mean reductions were significant (all P < .05) for all the parameters. The generalized estimating equation linear regression analyses of the 4 DCE-MRI parameters revealed that vascular normalization peaked 24 h after bevacizumab administration.
Bevacizumab induced vascular normalization of brain metastases in humans at 1 and 24 h after administration, and the effect was significantly higher at 24 h than at 1 h.
ClinicalTrials.gov, identifier NCT01281696 , registered prospectively on December 24, 2010.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab - administration & dosage</subject><subject>Bevacizumab - therapeutic use</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - blood supply</subject><subject>Brain Neoplasms - diagnostic imaging</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain tumors</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Contrast agents</subject><subject>Contrast Media - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Neoplasm</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neovascularization</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Prospective Studies</subject><subject>Response rates</subject><subject>Statistical analysis</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkltrFDEUxwdRbK1-AF8kIIg-TM1lMsm8CEvxUigIXp5DJnOymzKTrElmsX33e5tha90VCSHn8jsn5ORfVc8JPidEtm8ToVLyGpO2pk3X1PJBdUoaQYqHxcMD-6R6ktI1xkRILB9XJ1Q0hPKWnla_VmjrxpBRyvNwg3JAA2SIk_OA8qZsV8w10n5AYC2YjIJFPey0cbfzpHsUPNrpZOZRR-RDnPTobnV2JVzACbJOubgG9VE7j_I8hZhQsfoIJYWM9gbi0-qR1WOCZ3fnWfX9w_tvF5_qq88fLy9WV7XhvMs1azDFvJGslYYNRrSCGi06hgmhWLChp4QPhnFKJVBjmeV9R7rWMGt52w3Azqp3-77buZ9gMOBz1KPaRjfpeKOCduo4491GrcNOlek2HPPS4PVdgxh-zJCymlwyMI7aQ5iTIhI3koumwQV9-Q96Heboy_MWSnS0xYT9pdZ6BOW8DeVeszRVq6aVUgrSLtT5f6iyBpicCR6sK_GjgjdHBYXJ8DOv9ZySuvz65Zh9dcBuQI95k8I4L5-YjkGyB00MKUWw94MjWC2CVHtBqiJItQhSyVLz4nDi9xV_FMh-A-uA2lk</recordid><startdate>20160713</startdate><enddate>20160713</enddate><creator>Chen, Bang-Bin</creator><creator>Lu, Yen-Shen</creator><creator>Lin, Ching-Hung</creator><creator>Chen, Wei-Wu</creator><creator>Wu, Pei-Fang</creator><creator>Hsu, Chao-Yu</creator><creator>Yu, Chih-Wei</creator><creator>Wei, Shwu-Yuan</creator><creator>Cheng, Ann-Lii</creator><creator>Shih, Tiffany Ting-Fang</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160713</creationdate><title>A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer</title><author>Chen, Bang-Bin ; Lu, Yen-Shen ; Lin, Ching-Hung ; Chen, Wei-Wu ; Wu, Pei-Fang ; Hsu, Chao-Yu ; Yu, Chih-Wei ; Wei, Shwu-Yuan ; Cheng, Ann-Lii ; Shih, Tiffany Ting-Fang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c559t-34020548368c3dc7672ca7930112073db215dc35228e2cf3f5b9196c3ff569de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab - administration & dosage</topic><topic>Bevacizumab - therapeutic use</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - blood supply</topic><topic>Brain Neoplasms - diagnostic imaging</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain tumors</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Contrast agents</topic><topic>Contrast Media - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Neoplasm</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neovascularization</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Prospective Studies</topic><topic>Response rates</topic><topic>Statistical analysis</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Bang-Bin</creatorcontrib><creatorcontrib>Lu, Yen-Shen</creatorcontrib><creatorcontrib>Lin, Ching-Hung</creatorcontrib><creatorcontrib>Chen, Wei-Wu</creatorcontrib><creatorcontrib>Wu, Pei-Fang</creatorcontrib><creatorcontrib>Hsu, Chao-Yu</creatorcontrib><creatorcontrib>Yu, Chih-Wei</creatorcontrib><creatorcontrib>Wei, Shwu-Yuan</creatorcontrib><creatorcontrib>Cheng, Ann-Lii</creatorcontrib><creatorcontrib>Shih, Tiffany Ting-Fang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Bang-Bin</au><au>Lu, Yen-Shen</au><au>Lin, Ching-Hung</au><au>Chen, Wei-Wu</au><au>Wu, Pei-Fang</au><au>Hsu, Chao-Yu</au><au>Yu, Chih-Wei</au><au>Wei, Shwu-Yuan</au><au>Cheng, Ann-Lii</au><au>Shih, Tiffany Ting-Fang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2016-07-13</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>466</spage><epage>466</epage><pages>466-466</pages><artnum>466</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>To determine the appropriate time of concomitant chemotherapy administration after antiangiogenic treatment, we investigated the timing and effect of bevacizumab administration on vascular normalization of metastatic brain tumors in breast cancer patients.
Eight patients who participated in a phase II trial for breast cancer-induced refractory brain metastases were enrolled and subjected to 4 dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) examinations that evaluated Peak, Slope, iAUC 60 , and Ktrans before and after treatment. The treatment comprised bevacizumab on Day 1, etoposide on Days 2-4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles. DCE-MRI was performed before treatment and at 1 h, 24 h, and 21 days after bevacizumab administration.
Values of the 4 DCE-MRI parameters reduced after bevacizumab administration. Compared with baseline values, the mean reductions at 1 and 24 h were -12.8 and -24.7 % for Peak, -46.6 and -65.8 % for Slope, -27.9 and -55.5 % for iAUC 60 , and -46.6 and -63.9 % for Ktrans, respectively (all P < .05). The differences in the 1 and 24 h mean reductions were significant (all P < .05) for all the parameters. The generalized estimating equation linear regression analyses of the 4 DCE-MRI parameters revealed that vascular normalization peaked 24 h after bevacizumab administration.
Bevacizumab induced vascular normalization of brain metastases in humans at 1 and 24 h after administration, and the effect was significantly higher at 24 h than at 1 h.
ClinicalTrials.gov, identifier NCT01281696 , registered prospectively on December 24, 2010.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27412562</pmid><doi>10.1186/s12885-016-2494-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2016-07, Vol.16 (1), p.466-466, Article 466 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4944505 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Analysis Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Bevacizumab - therapeutic use Brain cancer Brain Neoplasms - blood supply Brain Neoplasms - diagnostic imaging Brain Neoplasms - drug therapy Brain Neoplasms - secondary Brain tumors Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer therapies Care and treatment Chemotherapy Cisplatin - administration & dosage Cisplatin - therapeutic use Clinical outcomes Contrast agents Contrast Media - administration & dosage Drug Administration Schedule Drug Resistance, Neoplasm Etoposide - administration & dosage Etoposide - therapeutic use Female Humans Hypotheses Magnetic resonance imaging Magnetic Resonance Imaging - methods Metastasis Middle Aged Neovascularization Patients Pilot Projects Prospective Studies Response rates Statistical analysis Time Factors Treatment Outcome Tumors |
| title | A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A10%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pilot%20study%20to%20determine%20the%20timing%20and%20effect%20of%20bevacizumab%20on%20vascular%20normalization%20of%20metastatic%20brain%20tumors%20in%20breast%20cancer&rft.jtitle=BMC%20cancer&rft.au=Chen,%20Bang-Bin&rft.date=2016-07-13&rft.volume=16&rft.issue=1&rft.spage=466&rft.epage=466&rft.pages=466-466&rft.artnum=466&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-016-2494-8&rft_dat=%3Cgale_pubme%3EA468887163%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1807926013&rft_id=info:pmid/27412562&rft_galeid=A468887163&rfr_iscdi=true |